Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5289

Shown on this page

Current sort

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

Terms that often appear in related listings

AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 433–444 of 5,289 matching trials for Leukemia.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection, Solid Cancers
Interventions: Diet Intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lymph Node Biopsy, Magnetic Resonance Imaging, Sonrotoclax, Zanubrutinib; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Duarte, California • Irvine, California • Newnan, Georgia

Conditions: AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
Interventions: SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose; Drug
Lead sponsor: BlueSphere Bio, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept; Drug · Radiation · Biological
Lead sponsor: Leland Metheny; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
Interventions: SOC+BSB-2002; Drug
Lead sponsor: BlueSphere Bio, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Lymphocytic Leukemia
Interventions: Inotuzumab Ozogamicin; Drug
Lead sponsor: Leland Metheny; Other
Eligibility: 16 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Leukemia Acute Myeloid
Interventions: Azacitidine, Venetoclax, Revumenib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: ibrutinib, venetoclax, Placebo; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 14
States / cities: Duarte, California • La Jolla, California • Orange, California + 11 more

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
Interventions: Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment; Other
Lead sponsor: Ossium Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 280
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more

Conditions: CD123+ Acute Myeloid Leukemia
Interventions: ORM-1153; Drug
Lead sponsor: Orum Therapeutics USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Houston, Texas

Conditions: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Columbus, Ohio

About this Leukemia clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Leukemia clinical trials

How Leukemia studies are organized in the registry

Filter and sort this condition

Live official records

High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology

Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

About this Leukemia clinical trials directory page